



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	1	Abeyasinghe, R.D., et al., "The environment of the lipoxygenase iron binding site explored with novel hydroxypyridine iron chelators," <i>J. of Biological Chem.</i> , 1996, 271(44), 7965-7972	
CA	2	Ahmed, S.I., et al., "The structures of bis-maltolato-zinc(II) and of bis-3-hydroxy-1,2-dimethyl-4-pyridinonato-zinc(II) and-lead(II)," <i>Polyhedron</i> , 2000, 19, 129-135	
CA	3	Barret, M.C., et al., "Synthesis and structural characterization of Tin(II) and Zinc(II) derivatives of cyclic $\alpha$ -hydroxyketones, including the structures of Sn(mltol) <sub>2</sub> , Sn(tropolone) <sub>2</sub> , Zn(tropolone) <sub>2</sub> , and Zn(hinokitiol) <sub>2</sub> ," <i>Inorg. Chem.</i> , 2001, 40, 4384-4388	
CA	4	Bebbington, D., et al., "3,5-disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)-pyridinone: potent inhibitors of lipid peroxidation and cell toxicity," <i>J. Med. Chem.</i> , 2000, 43, 2779-2782	
CA	5	Bickerdike, M.J., et al., "Enhanced acetylcholine release in striatum after chronic amphetamine is NMDA-dependent," <i>NeuroReport</i> , 1999, 10, 77-80	
CA	6	Bosquet, J.-C., et al., "Gd-DOTA: characterization of a new paramagnetic complex," <i>Radiology</i> , 1988, 166, 693-698	
CA	7	Branen, A.L., et al., "Use of antioxidants in self-preserving cosmetic and drug formulations," <i>Cosmet. Sci. Technol. Ser.</i> , 1997, 16, 159-179	
CA	8	Brewer, G.J., "Cooper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's Disease," <i>Exp. Biol. Med.</i> , 2001, 226(7), 665-673	
CA	9	CAPLUS Accession No. 1995:887972 (English abstract of Japanese Patent)	
CA	10	Caravan, P., et al., "Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications," <i>Chem. Rev.</i> , 1999, 99, 2293-2352	
EXAMINER		AWLAKH	DATE CONSIDERED 2-4-05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	11	Caravan, P., et al., "Reaction chemistry of BMOV, Bis(maltolato)oxovanadium(IV)—a potent insulin mimetic agent," <i>J. Am. Chem. Soc.</i> , <b>1995</b> , <i>117</i> , 12759-12770	
CA	12	Clarke, E.T., et al., "Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions," <i>Inorganica Chimica Acta</i> , <b>1992</b> , <i>191</i> , 57-63	
CA	13	Dobbin, P.S., et al., "Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential," <i>J. Med. Chem.</i> , <b>1993</b> , <i>36</i> , 2448-2458	
CA	14	Dutt, N.K., et al., "Chemistry of lanthanons—XL1. isolation and characterization of tris chelates of lanthanides with maltol, kojic acid and chloro-kojic acid," <i>J. Inorg. Nucl. Chem.</i> , <b>1975</b> , <i>37</i> , 1801-1802	
CA	15	Edwards, D.S., et al., "Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV)cations," <i>Inorg. Chem.</i> , <b>1994</b> , <i>33</i> , 5607-5609	
CA	16	Edwards, D.S., et al., "Potential <sup>99m</sup> Tc radiopharmaceuticals for renal imaging: tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato)technetium(IV)cations," <i>Nucl. Med. Biol.</i> , <b>1993</b> , <i>20</i> (7), 857-863	
CA	17	El-Jammal, A., et al., "Cooper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies," <i>J. Med. Chem.</i> , <b>1994</b> , <i>37</i> , 461-466	
CA	18	Ellis, B.L., et al., "6-alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labeling with indium," <i>Eur. J. Nucl. Med.</i> , <b>1999</b> , <i>26</i> , 1400-1406	
CA	19	Ellis, B.L., et al., "Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling," <i>J. med. Chem.</i> , <b>1996</b> , <i>39</i> , 3659-3670	
CA	20	Faller, B., et al., "Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network," <i>J. Med. Chem.</i> , <b>2000</b> , <i>43</i> , 1467-1475	
EXAMINER		ASLAKH	DATE CONSIDERED 2-4-05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	21	Fernandez, J.A., et al., "Essential viral and cellular zinc and iron containing metalloproteins as targets for novel antiviral and anticancer agents: implications for prevention and therapy of viral diseases and cancer," <i>Anticancer Res.</i> , 2001, 21, 931-958	
CA	22	Ferrali, M., et al., "3-hydroxy-(4H)-benzopyran-4-ones as potential iron chelating agents in vivo," <i>Bioorganic &amp; Medicinal Chem.</i> , 2001, 9, 3041-3047	
CA	23	Foda, H.D., et al., "Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis," <i>DDT</i> , 2001, 9, 478-482	
CA	24	Gutteridge, J.M.C., et al., "Iron toxicity and oxygen radicals," <i>Ballièr's Clin. Haematology</i> , 1989, 2(2), 195-256	
CA	25	Gwyn, K., et al., "Breast cancer during pregnancy," <i>Oncology</i> , 2001, 15(1), 39-46	
CA	26	Hashimoto, M., et al., "Oxidative stress induces amyloid-like aggregate formation of NACP/ $\alpha$ -synuclein in vitro," <i>NeuroReport</i> , 1999, 10, 717-721	
CA	27	Henrotin, Y., et al., "The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives," <i>Expert Opin. Ther. Patents</i> , 2002 12(1), 29-43	
CA	28	Hidalgo, M., et al., "Development of matrix metalloproteinase inhibitors in cancer therapy," <i>J. of the National Cancer Institute</i> , 2001, 93(3), 178-193	
CA	29	Hider, R.C., et al., "Design of orally active iron chelators," <i>Acta Haematol</i> , 1996, 95, 6-12	
CA	30	Hu, T.C.-C., et al., "Manganese-enhanced MRI of mouse heart during changes in inotropy," <i>Magnetic Resonance in Medicine</i> , 2001, 46, 884-890	
EXAMINER		AULAKH	DATE CONSIDERED 2. 4. 05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	31	Hunter, D.R., et al., "Comparison of $\text{Ca}^{2+}$ , $\text{Sr}^{2+}$ , and $\text{Mn}^{2+}$ fluxes in mitochondria of the perfused rat heart," <i>Circ. Res.</i> , 1980, 47, 721-727	
CA	32	John A., et al., "The role of matrix metalloproteinases in tumor angiogenesis of tumor metastasis," <i>Pathology Oncology Res.</i> , 2001, 7(1), 14-23	
CA	33	Liu, Z.D., et al., "Design, synthesis and evaluation of <i>N</i> -basis substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotropic potential," <i>J. Pharm. Pharmacol.</i> , 2000, 52, 263-272	
CA	34	Liu, Z.D., et al., "Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase," <i>Biochem. Pharmac.</i> , 2001, 285-290	
CA	35	Liu, Z.D., et al., "Synthesis of 2-amido-3-hydroxypyridin-4(1 <i>H</i> )-ones: novel iron chelators with enhanced $\text{pFe}^{3+}$ values," <i>bioorganic &amp; Medicinal Chem.</i> , 2001, 9, 563-573	
CA	36	Magerstädt, M., et al., "Gd(DOTA): an alternative to Gd(DTPA) as a $T_{1\rho}$ relaxation agent for NMR imaging or spectroscopy," <i>Magnetic Resonance in Medicine</i> , 1986, 3, 808-812	
CA	37	Martell, A.E., et al., "New chelating agents suitable for the treatment of iron overload," <i>Inorganica Chimica Acta</i> , 1999, 291, 238-246	
CA	38	Matthews, A.J., et al., "Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1)," <i>J. of Surg. Res.</i> , 1997, 73, 35-40	
CA	39	McCawley, L.J., et al., "Matrix metalloproteinases: multifunctional contributors to tumor progression," <i>Molecular Medicine Today</i> , 2000, 6, 149-156	
CA	40	McNeill, J.H., et al., "Bis(maltolato)oxovanadium(IV) is a potent insulin mimic," <i>J. Med. Chem.</i> , 1992, 35, 1489-1491	
EXAMINER		AULAKH	DATE CONSIDERED 2-4-05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	41	Melchoir, M., et al., "Vanadium complexes as insulin mimetic agents: coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolate, thiazolate, or picolinate units," <i>Inorg. Chem.</i> , <b>1999</b> , <i>38</i> , 2288-2293	
CA	42	Molenda, J.J., et al., "Enhancement of iron excretion via monoanionic 3-hydroxypyrid-4-ones," <i>J. Med. Chem.</i> , <b>1994</b> , <i>37</i> , 93-98	
CA	43	Narita, K., et al., "Mn and Mg influxes through Ca channels of motor nerve terminals are prevented by verapamil in frogs," <i>Brain Res.</i> , <b>1990</b> , <i>510</i> , 289-295	
CA	44	Naughton, D.P., et al., "EDTA bis-(ethyl phenylalaninate): a novel transition metal-ion chelating hydroxyl radical scavenger with a potential anti-inflammatory role," <i>Bioorganic &amp; Medicinal Chem. Letts.</i> , <b>2001</b> , <i>11</i> , 2573-2575	
CA	45	Piyamongkol, S., et al., "Novel synthetic approach to 2-(1'-hydroxyalkyl)-and 2-amido-3-hydroxypyridin-4-ones," <i>Tetrahedron</i> , <b>2001</b> , <i>57</i> , 3479-3486	
CA	46	Porter, J.B., "A risk-benefit assessment of iron-chelation therapy," <i>Drug Safety</i> , <b>1997</b> , <i>17(6)</i> , 407-421	
CA	47	Rai, B.L., et al., "Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential," <i>Eur. J. Med. Chem.</i> , <b>1999</b> , <i>34</i> , 475-485	
CA	48	Rai, B.L., et al., "Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones," <i>J. Med. Chem.</i> , <b>1998</b> , <i>41</i> , 3347-3359	
CA	49	Rangel, M., "Pyridinone oxovanadium(IV) complexes: a new class of insulin mimetic compounds," <i>Transition Metal Chem.</i> , <b>2001</b> , <i>26</i> , 219-223	
CA	50	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., <i>Mack Publishing Co.</i> , <b>1985</b> , page 1418	
EXAMINER		AULAKH	DATE CONSIDERED 2-4-05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	51	Runge, V.M., "Safety of approved MR contrast media for intravenous injection," <i>J. of Magnetic Resonance Imaging</i> , 2000, 12, 205-213	
CA	52	Runge, V.M., et al., "MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA," <i>Radiology</i> , 1988, 166, 835-838	
CA	53	Sakurai, H., et al., "Cysteine methyl ester-oxovanadium(IV) complex, preparation and characterization," <i>Inorganica Chimica Acta</i> , 1980, 46, L119-L120	
CA	54	Shibuya, I., et al., "Indications from Mn-quenching of fura-2 fluorescence in melanotrophs that dopamine and baclofen close Ca channels that are spontaneously open by not those opened by high $[K^+]_o$ , and that Cd preferentially blocks the latter," <i>Cell Calcium</i> , 1993, 14, 33-44	
CA	55	Singh, S., et al., "Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones," <i>Drug Metabolism and Disposition</i> , 1992, 20(2), 256-261	
CA	56	Skiles, J.W., et al., "The design, structure and therapeutic application of matrix metalloproteinase inhibitors," <i>Curr. Med. Chem.</i> , 2001, 8, 425-474	
CA	57	Streater, M., et al., "Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties, and biological activity," <i>J. Med. Chem.</i> , 1990, 33, 1749-1755	
CA	58	Thomas, et al., "Chemotherapeutic studies in the heterocyclic series. Reaction of kojic acid with hydrazine. Reaction of kojic acid ethers with hydrazine," <i>Helvetica Chimica Acta</i> , 1960, 43, 469-477	
CA	59	Thompson, K.H., et al., "Coordination chemistry of vanadium in metallopharmaceutical candidates compounds," <i>Coordination Chem. Rev.</i> , 2001, Vol. 219-221, 1033-1053	
CA	60	Thompson, K.H., et al., "Design of vanadium compounds as insulin enhancing agents," <i>J. Chem. Soc., Dalton Trans.</i> , 2000, 2885-2892	
EXAMINER		ALLAKH	DATE CONSIDERED 2-4-05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CA	61	Whittaker, M., et al., "Design and therapeutic application of matrix metalloproteinase inhibitors," <i>Chem. Rev.</i> , 1999, 99, 2735-2776	
CA	62	Yuen, V.G., et al., "Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration," <i>Can. J. of Physiol. Pharmacol.</i> , 1995, 73, 55-64	
CA	63	Yuen, V.G., et al., "Glucose-lowering properties of vanadium compounds: comparison of coordination complexes with maltol or Kojic acid as ligands," <i>J. of Inorganic Biochem.</i> , 1997, 68, 109-116	
CA	64	Yuen, V.G., et al., "Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on <i>fa/fa</i> Zucker rats," <i>Can. J. Physiol. Pharmacol.</i> , 1996, 74, 1001-1009	
CA	65	Zhang, Z., et al., "Potential <sup>67</sup> Ga radiopharmaceuticals for myocardial imaging: Tris(1-aryl-3-hydroxy-2-methyl-4-pyridinonato)gallium(III) complexes," <i>Nucl. Med. Biol.</i> , 1992, 19(3), 327-335	
CA	66	Dobbin, P.S., et al., "Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential," <i>J. Med. Chem.</i> , 1993, 36, 2448-2458	
CA	67	Edwards, D.S., et al., "Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV) cations," <i>Inorg. Chem.</i> , 1994, 33, 5607-5609	
CA	68	Melchior, M., "Vanadium complexes as insulin mimetic agents: coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolate, thiazolate, or picolinate units," <i>Inorg. Chem.</i> , 1999, 38, 2288-2293	
CA	69	Rai, B.L., et al., "Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones," <i>J. Med. Chem.</i> , 1998, 41, 3347-3359	
EXAMINER		AWLAKH	DATE CONSIDERED 2-4-05

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

## U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
CA	70	4,908,371	03/13/90	Moerker, et al.	514	318
CA	71	5,087,440	02/11/92	Cacheris, et al.	424	9
CA	72	5,155,215	10/13/92	Ranney	534	16
CA	73	5,256,676	10/26/93	Hider, et al.	514	348
CA	74	5,525,326	06/11/96	Unger	424	9.36
CA	75	5,527,790	06/18/96	McNeill, et al.	514	186
CA	76	5,688,815	11/18/97	Zbinden, et al.	514	348
CA	77	5,716,598	02/10/98	Golman, et al.	424	9.36
CA	78	5,866,563	02/02/99	McNeil, et al.	514	186
CA	79	5,877,210	03/02/99	Schieven	514	492
CA	80	5,980,863	11/09/99	Harnish, et al.	424	9.36
CA	81	6,046,219	04/04/00	Hanauske-Abel, et al.	514	348
CA	82	6,294,152 B1	09/25/01	Davies, et al.	424	9.361
CA	83	6,323,340 B1	05/15/01	Zhang, et al.	514	492
CA	84	2,136,807	11/15/38	Stoker	110	48
CA	85	6,232,340	05/15/01	Zhang, et al.	514	492
EXAMINER			DATE CONSIDERED			
AWAKH			2-4-05			



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
CA	86	WO 91/12822	09/05/91	PCT		
CA	87	WO 93/10822	06/10/93	PCT		
CA	88	WO 96/05867	02/29/96	PCT		
CA	89	WO 96/22021	07/25/96	PCT		
CA	90	WO 96/41639	12/27/96	PCT		
CA	91	WO 97/02842	01/30/97	PCT		
CA	92	WO 98/54138	12/03/98	PCT		
CA	93	WO 99/23075	05/14/99	PCT		
CA	94	WO 99/30562	06/24/99	PCT		
CA	95	WO 00/16736	03/30/00	PCT		
CA	96	WO 00/16782	03/30/00	PCT		
CA	97	WO 00/24730	05/04/00	PCT		
CA	98	WO 01/12168	02/22/01	PCT		
CA	99	0 335 745	10/04/89	EPO		
CA	100	1 006 108	06/07/00	EPO		
CA	101	1 006 112	06/07/00	EPO		
CA	102	2 269 589	02/16/94	UK		
EXAMINER				ALLAKH	DATE CONSIDERED	
					2-4-05	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
CA	103	2 345 058	06/28/00	UK		
CA	104	07 179 474	07/18/95	JP		
CA	105	WO 98/01458	01/15/98	PCT	X abstract	
CA	106	0 316 279 A2	05/17/89	EP	X abstract	
EXAMINER		ALUAKM		DATE CONSIDERED 2-4-05		